Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.78 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8006768 | 0.88 | FGFR1 (1.00) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL19911357 | 0.86 | HTT (0.76) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| Hydrochloric Acid SCHEMBL7989899 | 0.86 | FGFR1 (0.97) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL7989907 | 0.85 | HTT (0.74) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL19350738 | 0.85 | FGFR1 (0.79) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL14491107 | 0.84 | HTT (0.72) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL18609552 | 0.84 | KDR (0.74) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL18280702 | 0.81 | FGFR1 (1.00) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL10695254 | 0.81 | HTT (1.00) | HTTALDH1A1HPGDMAPK1MAPK10 | |
| SCHEMBL19781592 | 0.80 | HTT (0.67) | HTTALDH1A1HPGDMAPK1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | claimed |
| EP-2173721-B1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-28 | — | — | EP | claimed |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | claimed |
| EP-2173721-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | claimed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2173721-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| US-6218388-B1 | THERAPY OF PROTEIN TYROSINE KINASE MEDIATED CANCER, ATHEROSCLEROSIS, RESTENOSIS, AND PSORIASIS BY ADMINISTERING BENZIMIDAZOLE DERIVATIVE | WARNER-LAMBERT COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-5990146-A | TREATING PROTEIN TYROSINE KINASE MEDIATED CANCER; ANTICARCINOGENIC AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS; ANTIPROLIFERATIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | AZI2, NISCH, UQCRB | HTT 3225/4885ALDH1A1 97/4885HPGD 1659/4885 |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | HTT 1107/4885ALDH1A1 3497/4885HPGD 2179/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | HTT 1107/4885ALDH1A1 3497/4885HPGD 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.